Tapinarof is under clinical development by Dermavant Sciences and currently in Phase III for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase III drugs for Atopic Dermatitis (Atopic Eczema) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tapinarof’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tapinarof (Symbiox, Benvitimod, Vtama) is a non-steroidal anti-inflammatory and immunomodulating agent. It is formulated as cream for topical application. Symbiox is indicated for the treatment of adults with mild to moderate stable psoriasis vulgaris. Vtama is indicated for the topical treatment of plaque psoriasis in adults.
Tapinarof (GSK-2894512, WBI-1001, RVT-505, DMVT-505) is under development for the treatment of localized scleroderma, plaque psoriasis and atopic dermatitis. It acts by targeting aryl hydrocarbon receptor (AhR) and Tyrosine-protein kinase Tec. The drug candidate is formulated as a cream and is administered through topical route. The drug candidate is developed based on the symbiochem drug discovery platform. It was also under development for the treatment of atopic dermatitis and plaque psoriasis in China.
For a complete picture of Tapinarof’s drug-specific PTSR and LoA scores, buy the report here.